Join our global network with a Mitacs program

Trainees are an integral part of the 20 years SGC global network of over 250 scientists. Since 2015, we've proudly partnered with Mitacs, offering over 550 internship units to trainees across 25+ unique projects, totaling $8.4M. This direct support funds trainee stipends and research costs.

We're honored to be recognized as one of Mitacs top partners nationwide. Winning the 2021 Mitacs Award for Exceptional Leadership-Industry was just the beginning! Through the Mitacs Accelerate Supercluster, "Genes to Affordable Medicines," we've secured $6.48M to provide multidisciplinary experience and training to 63 post-doctoral fellows, who will spend 2-3 years developing open-source tools and knowledge for previously understudied proteins, unlocking new areas of biology and identifying opportunities for drug discovery. 

Our initiative includes six research programs: structural biology, medicinal chemistry, chemical biology, antibody validation, patient-derived disease models, and open science drug development. Through our connection to the SGC charity, trainees will have the opportunity to collaborate on AI-enabled drug discovery projects with our esteemed pharmaceutical company partners, including Bayer AG, Boehringer Ingelheim, Genentech, Janssen, Merck, Pfizer, Takeda, and Bristol Myers Squibb as well as AI companies like Cyclica, Atomwise, Molecular Forecaster, Valence Discovery, and Ventus Therapeutics. 

By joining us, trainees gain hands-on exposure to academic and industry collaborations, expanding their career options. Many Mitacs-SGC alumni are now academic or business leaders, holding prestigious positions in renowned institutions or scientific leadership roles in major pharmaceutical companies.

Together with Mitacs, we are proud to support the development of the next generation of scientific leaders, fostering open science and collaboration. Join us to become a part of SGC's unique research program, providing an unparalleled learning experience in Canada. SGC Careers | SGC (

Learn more: Consortium removes barriers to drug discovery, raises hope for rare disease cures | Mitacs

glqxz9283 sfy39587stf02 mnesdcuix8